<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id>
      <journal-title-group>
        <journal-title>BMC Gastroenterology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-230X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25986067</article-id>
      <article-id pub-id-type="pmc">4461943</article-id>
      <article-id pub-id-type="publisher-id">288</article-id>
      <article-id pub-id-type="doi">10.1186/s12876-015-0288-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Solbach</surname>
            <given-names>Philipp</given-names>
          </name>
          <address>
            <email>solbach.philipp@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Potthoff</surname>
            <given-names>Andrej</given-names>
          </name>
          <address>
            <email>potthoff.andrej@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Raatschen</surname>
            <given-names>Hans-J&#xFC;rgen</given-names>
          </name>
          <address>
            <email>raatschen.hans-juergen@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Soudah</surname>
            <given-names>Bisharah</given-names>
          </name>
          <address>
            <email>soudah.bisharah@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lehmann</surname>
            <given-names>Ulrich</given-names>
          </name>
          <address>
            <email>lehmann.ulrich@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schneider</surname>
            <given-names>Andrea</given-names>
          </name>
          <address>
            <email>schneider.s.andrea@gmx.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gebel</surname>
            <given-names>Michael J.</given-names>
          </name>
          <address>
            <email>gebel.michael@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manns</surname>
            <given-names>Michael P.</given-names>
          </name>
          <address>
            <email>manns.michael@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vogel</surname>
            <given-names>Arndt</given-names>
          </name>
          <address>
            <email>vogel.arndt@mh-hannover.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, OE 6810 Carl-Neuberg-Str. 1, 30625 Hannover, Germany </aff>
        <aff id="Aff2"><label>2</label>Department of Diagnostic and Interventional Radiology, Medizinische Hochschule Hannover, Hannover, Germany </aff>
        <aff id="Aff3"><label>3</label>Department of Pathology, Medizinische Hochschule Hannover, Hannover, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>20</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>60</elocation-id>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>1</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>5</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Solbach et al. 2015</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Continuous use of anabolic androgenic steroid in high-doses is associated with substantial health risks, including hepatocellular adenoma. Malignant transformation from hepatocellular adenoma to hepatocellular carcinoma after anabolic androgenic steroid abuse has been rarely reported. The morphological distinction of adenoma from well-differentiated hepatocellular carcinoma is challenging and requires elaborated imaging techniques and histology.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report about a 29-year old male professional bodybuilder who presented with mid-epigastric pain at the emergency unit. Ultrasound showed a severe hepatomegaly with multiple lesions. Contrast-enhanced ultrasound revealed a heterogeneous pattern with signs of hepatocellular carcinoma. CT scan of the abdomen confirmed multiple hypervascular lesions and central areas of necrosis without contrast enhancement. Subsequent diagnostics included fine needle aspiration (FNA) of suspicious lesions and mini-laparoscopy to establish the diagnosis of a &#x3B2;-catenin and testosterone-receptor positive hepatocellular carcinoma embedded in multiple adenomas. The patient was subsequently treated by liver transplantation and remains tumor-free 27&#xA0;month after surgery.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Hepatocellular carcinoma occurring in association with anabolic androgenic steroid abuse should sensitize physicians and especially professional bodybuilders for the harmful use of high doses of steroids.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Anabolic androgenic steroids</kwd>
        <kwd>Hormonal treatment</kwd>
        <kwd>Hepatocellular carcinoma</kwd>
        <kwd>Hepatic adenoma</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>One of the major risk factors of developing hepatocellular adenoma (HCA) is the use of oral contraceptives, which stimulate liver expressed estrogen and androgen receptors, predominantly in women between 15 and 45&#xA0;years of age [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Accordingly, 90&#xA0;% of HCA are diagnosed in women [<xref ref-type="bibr" rid="CR3">3</xref>]. Other risk factors include glycogen storage disease I and III and treatment with anabolic steroids in patients with Fanconi&#x2019;s anemia [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR6">6</xref>]. A few reports indicate that anabolic androgenic steroids (AAS) may also lead to the formation of HCA [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. Relevant complications of HCA include hemorrhage and malignant transformation into hepatocellular carcinoma (HCC) depending on size and &#x3B2;-catenin activation.</p>
      <p>In the literature are more reports of patients with Fanconi&#x2019;s anemia, which received medical treatment with AAS and subsequently developed HCCs [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore a few cases are described from bodybuilders with AAS abuse that subsequently developed HCC [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. These patients require close surveillance to detect possible malignant transformation from HCA into HCC or lesions that are at risk of bleeding or rupture [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>Here, we report a case of a testosterone-receptor positive HCC arising from multiple HCAs in a professional bodybuilder after 6&#xA0;years of AAS abuse and the difficulties of diagnostics and therapeutical options.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <sec id="Sec3">
        <title>Clinical history</title>
        <p>We describe a case of a 29-year old male professional bodybuilder who presented at the emergency unit with midepigastric-pain. He had been taking anabolic androgenic steroids (AAS; see below) and underwent strict nutritional diets to increase muscle mass prior to competitions over the last 6&#xA0;years. He self-administered the following AAS from 2011 to 2012 in cycles of 4&#xA0;weeks with rest periods of several weeks between the cycles: nandrolone decanoate (400&#xA0;mg/week), sustanon (750&#xA0;mg/week), methandienone (280&#x2013;350&#xA0;mg/week), stanozolol (50&#xA0;mg/day for 1&#xA0;month) and human growth hormone (4&#xA0;IE/day for 3&#xA0;month). Additionally 3&#xA0;days before competitions he self-administered the diuretics aldosterone (50&#xA0;mg/day) and thiazide (25&#xA0;mg/day) to reduce extracellular and subcutaneous tissue volume and to achieve a better muscle shaping. Furthermore insulin injections and tamoxifen were administered. The frequency of self-administration was varying in each cycle.</p>
        <p>At presentation, the patient had not taken any AAS for 5&#xA0;weeks. Previous history was a childhood near a nuclear power plant until the age of fifteen. Allergic coryza and nasal spray use since the age of seven were reported. Moreover no abuse of ethanol or smoking was given. The patient&#x2019;s father died supposedly as the result of kidney cancer, his grandfather died from bronchial cancer. His mother and younger siblings are healthy. On examination, the patient showed a three-fold amplified liver extending into lesser pelvis with painful palpation. No other clinical abnormalities were detectable (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Clinical examination showed a muscular body, height 186&#xA0;cm, weight 120&#xA0;kg. The lung showed a sonorous percussion, vesicular breath sounds, no noise. Heart: regular rhythm, 55&#xA0;bpm, RR 134/67&#xA0;mmHg, first heart sound and second heart sound not flashy, no heart murmurs. No pathological examination findings for head, neck, lymph node status, pulse status. No scleral icterus. Abdominal examination showed a large abdomen, vascular abdominal markings, yellow colouring, liver palpable to lesser pelvis right, superficial palpation was painful, spleen not palpable, no kidney pain or back pain (<bold>a</bold> lateral view; <bold>b</bold> ventral view)</p></caption><graphic xlink:href="12876_2015_288_Fig1_HTML" id="d30e514"/></fig></p>
      </sec>
      <sec id="Sec4">
        <title>Laboratory findings</title>
        <p>Laboratory evaluation revealed severe hepatic inflammation and an impaired liver function (ALT 1653&#xA0;IU/l; AST 1437&#xA0;IU/l; alkaline phosphatase 372&#xA0;IU/l; GGT 463&#xA0;IU/l; CHE 1.29 kU/I; LDH 695 U/I; total bilirubin 41&#xA0;&#x3BC;mol/l; direct bilirubin 38&#xA0;&#x3BC;mol/l). Hematology showed an anemia and slightly increased white blood cell count (leucocytes 12.500/ &#x3BC;l; hemoglobin 8.5&#xA0;g/dl; INR 1.04; reticulocytes 104/nl). Inflammation parameters were increased (CRP 81&#xA0;mg/l, PCT 4.8&#xA0;&#x3BC;g/l, Ferritin 1672&#xA0;&#x3BC;g/l). The renal function was almost normal (creatinine 123&#xA0;&#x3BC;mol/l, but cystatine c 0.76&#xA0;mg/l and MDRD&#x2009;&gt;&#x2009;60&#xA0;ml/min).</p>
        <p>Coagulation tests were normal, as well as hepatitis virus markers, including hepatitis A, B and C and also human deficiency virus markers were negative. Serum levels of sex hypophyseal hormones (LH &lt;0.07 U/I, FSH &lt;0.3 U/I, androgens (T&#x2009;+&#x2009;DHT) 0.037&#xA0;ng/ml, free-testosterone 4.94&#xA0;pg/ml) and thyroid gland markers (fT3, fT4) were below the lower limit of normal. This constellation of sex hormones reflects anabolic steroids induced hypogonadism (ASIH).</p>
      </sec>
      <sec id="Sec5">
        <title>Imaging</title>
        <p>Abdominal ultrasound (US) showed a marked hepatomegaly with 25.6&#xA0;cm in the midclavicular line and 30.1&#xA0;cm in the median with evidence of fatty liver. In B-mode sonography multiple lesions were detected in both liver lobes (left liver lobe: various isoecogenic, inhomogeneous lesions with a maximum size of 92&#xA0;mm &#xD7; 92&#xA0;mm; right liver lobe: various isoecogenic, polycyclic inhomogeneous lesions with a maximum size of 222&#xA0;mm &#xD7; 162&#xA0;mm) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a). Moreover, the hepatic segment of the inferior vena cava (IVC) was compressed by the hepatic tumors, which consecutively led to a partial Budd Chiari syndrome. This was diagnosed in the doppler sonography through the retrograde flow pattern in the right hepatic vein with an evidence of subcapsular venous collaterals.<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>a</bold> B-mode ultrasonography: The hepatic tumors were polycyclic, isoechoic and inhomogeneous. Doppler sonography showed a compression in the IVC hepatic segment by the liver tumors with consecutive development of partial Budd Chiari syndrome diagnosed by the retrograde flow pattern in the right hepatic vein and the presence of subcapsular venous collaterals. <bold>b</bold> Contrast enhanced ultrasonography (CEUS): CEUS was performed using a bolus injection of 1.5&#xA0;mL SonoVue&#xAE; (Bracco SpA, Milan, Italy). The largest lesion showed a large, avascular center with hypervascular margin in the arterial phase. In the late venous phase parts of the center and the margin showed wash-out</p></caption><graphic xlink:href="12876_2015_288_Fig2_HTML" id="d30e543"/></fig></p>
        <p>In contrast-enhanced ultrasound (CEUS) the hepatic lesions showed a heterogeneous pattern (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b). Some lesions exhibited arterial enhancement, initially at the periphery with subsequent very rapid centripetal filling and without wash-out in the portal venous or late phase. Other lesions showed arterial enhancement, with a chaotic vascular pattern and avascular areas in different parts of each tumor. In the portal venous phase, these tumors showed wash-out, especially in liver segment 6, in which a tumor biopsy was performed. The small lesions (diameter &lt;12&#xA0;mm) seen in B-mode sonography showed neither arterial hypervascularisation nor wash-out in the portal venous or late phase. The contrast-enhanced CT scan of the abdomen revealed a distinctive hepatomegaly with multiple hypervascular lesions without substantial wash-out in portal venous phase. In the largest lesions, central areas of necrosis without contrast enhancement were present (16 &#xD7; 13&#xA0;cm) (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). There was no evidence of metastasis in the abdomen and chest.<fig id="Fig3"><label>Fig. 3</label><caption><p>Contrast enhanced computed tomography in arterial (<bold>a</bold>,<bold>c</bold>) and portalvenous phase (<bold>b</bold>,<bold>d</bold>): Highly enlarged liver with curved borders secondary to multiple parenchymatous lesions throughout all liver segments, with arterial enhancement and no substantial wash-out during portalvenous phase. The large lesion in right lobe up to 16&#xA0;cm appeared inhomogeneous with peripheral enhancement and non-enhancing, necrotic areas in the center. Intrahepatic vena cava and right liver vein were completely compressed by nodular tumors in the caudate lobe and the large lesion in the right lobe</p></caption><graphic xlink:href="12876_2015_288_Fig3_HTML" id="d30e572"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Pathology</title>
        <p>Cytology of liver-segment six was performed by fine needle aspiration (FNA) of one lesion with signs of hepatocellular carcinoma in contrast-enhanced ultrasound. The cytological samples did not reveal malignancy and showed no clearly signs for hepatocellular carcinoma or hepatoblastoma. Further molecular cytogenetic and pathological-anatomical diagnostics showed atypical HCA.</p>
        <p>To confirm the diagnosis of hepatocellular carcinoma in suspicious lesions, a diagnostic laparoscopy was performed. The liver was enormously enlarged and there was almost no veritable parenchyma visible between the tumor nodules. The largest tumors bulged out of the liver&#x2019;s surface with yellow to bluish discoloration and strong tumor vascular markings. Biopsy of the liver in the right lobe from three tumors and one tumor of the left lobe was performed. The synopsis of morphology and immunohistochemistry now clearly confirmed the diagnosis of a hepatocellular carcinoma (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>d; &#x3B2;-catenin 20% nuclear positive (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>a), glutamine synthetase cytoplasmic positive (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>b), androgen-receptor nuclear positive (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>c) and focal CD34 positive). Sequence analysis of exon 3 of the &#x3B2;-catenin gene was performed by PCR and subsequent Sanger sequencing as described in reference eleven and showed a hotspot mutation in codon 32 (p.D32G) [<xref ref-type="bibr" rid="CR11">11</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>Liver biopsy: Small solid and glandular associations of hepatocytes without bile duct epithelia. Reticulin fiber network focally obtained. The hepatocytes had markedly enlarged nuclei with large nucleoli with coarse structure of chromatin. Iron and rhodanine negative. Immunohistochemistry: Beta-catenin 20&#xA0;% nuclear positive (<bold>a</bold>; 80:1) and glutamine synthetase cytoplasmic positive (<bold>b</bold>; 160:1), hepatocytes with nuclear positivity for androgen-receptors (<bold>c</bold>; 140:1). Molecular Cytogenetics: Aneuploidy of chromosome 1 (CEP1) and 8 (CEP). Diagnosis: The results of conventional histology, molecular biology and immunohistochemistry recommended HCC G1 (<bold>d</bold>; HE stain 140:1). Comment: Simply by Cytology (FNP) a detection of HCC G1 is quite difficult. There were no bridges or cell atypia, on the other hand, histology showed more criteria for HCC G1</p></caption><graphic xlink:href="12876_2015_288_Fig4_HTML" id="d30e616"/></fig></p>
      </sec>
      <sec id="Sec7">
        <title>Treatment</title>
        <p>Due to the size and number of the lesions, there was no option for surgical resection. The distinction of all tumor nodules into HCAs and hepatocellular carcinomas was impossible, but overall HCC burden was considered to be out of the Milan criteria [<xref ref-type="bibr" rid="CR12">12</xref>]. The multidisciplinary tumor board at Medical School Hannover initially recommended chemoembolization, which was however declined by the patient. He therefore returned home, where subsequently a liver transplantation was performed without any complications. The explanted liver showed a mass of 8 kg. 27&#xA0;months after transplantation he is in excellent condition without any signs of metastasis or local recurrence. He is not taking AAS anymore.</p>
      </sec>
      <sec id="Sec8">
        <title>Discussion</title>
        <p>We report a case of a young professional bodybuilder with self-administration of high-doses of anabolic androgenic steroids (AAS) for at least 6&#xA0;years who developed a hepatocellular carcinoma (HCC) without metastasis or alpha-fetoprotein elevation. In this case, the hepatocellular carcinoma was embedded in multiple hepatocellular adenomas (HCA).</p>
        <p>AAS such as testosterone and its derivates are favored in endurance and strength sports as well as in bodybuilding, often in combination with other medication like diuretics and insulin. The most popular oral products especially stanozolol, methandrostenolone and nandrolone have a high first-pass in the liver and have been reported to induce significant toxicity including intrahepatic structural changes with cholestasis and benign and malignant tumors.</p>
        <p>It has been reported, that steroids induce HCA with potential malignant transformation into carcinoma. As described for colorectal-carcinoma, there could be an adenoma-carcinoma sequence [<xref ref-type="bibr" rid="CR13">13</xref>]. In our case, it is difficult to distinguish whether the HCC developed de novo or within the multiple HCAs. Several biopsies from multiple tumor nodules were required to ascertain the diagnosis of HCC. The morphological distinction of HCA, focal nodular hyperplasia (FNH), macroregenerative nodules from well-differentiated HCC can be challenging [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
        <p>Malignant transformation of HCA may occur in about 4.5&#x2013;9&#xA0;% of cases [<xref ref-type="bibr" rid="CR14">14</xref>&#x2013;<xref ref-type="bibr" rid="CR17">17</xref>]. Exome sequencing has identified recurrent somatic activating mutations in several genes including FRK, JAK1, gp130, and &#x3B2;-catenin. Moreover, integrative analysis of HCAs transformed to hepatocellular carcinoma revealed that &#x3B2;-catenin mutation occurs as an early alteration, whereas TERT promoter mutations are associated with the last step of the adenoma-carcinoma transition [<xref ref-type="bibr" rid="CR18">18</xref>]. HCAs with &#xDF;-catenin mutations frequently show an overexpression of &#x3B2;-catenin (nuclear and cytoplasmic) and glutamine synthetase as in our patient. Although HCA shows an increased prevalence in women, beta-catenin activation is more prevalent in men with consequently an increased prevalence of HCC [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In our case genetic analysis for &#x3B2;-catenin mutations showed a hotspot mutation in codon 32 of exon 3 (p.D32G).</p>
        <p>As has been described previously, HCA showed highly variable appearance on computed tomography (CT), magnetic resonance imaging (MRI), and contrast-enhanced ultrasound (CEUS) scans. This is reflected by the differences in the histological features [<xref ref-type="bibr" rid="CR21">21</xref>&#x2013;<xref ref-type="bibr" rid="CR25">25</xref>]. In the CEUS, typical HCA shows an arterial hypervascularisation in the early arterial phase with a centripetal filling pattern. However this arterial enhancement pattern can also be encountered in HCC and is not pathognomonic of HCA [<xref ref-type="bibr" rid="CR26">26</xref>]. MRI seems to be superior to other imaging modalities for the diagnosis of HCA. One study performed by <italic>Laumonier</italic> and coworkers revealed that in hepatocyte nuclear factor 1 alpha (HNF1A) -mutated and inflammatory HCAs characteristic MRI patterns exist, which reach a specificity of 100&#xA0;% and a sensitivity of 86.7&#xA0;% [<xref ref-type="bibr" rid="CR27">27</xref>]. Histology is the ultimate gold standard for the diagnosis and risk stratification of HCAs [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
        <p>Immunochemistry analysis revealed the presence of testosterone-receptors on the hepatocellular carcinoma, which might be of prognostic significance. In one study, none of the patients with androgen receptor (AR) positive HCC survived 5&#xA0;years [<xref ref-type="bibr" rid="CR29">29</xref>]. Other studies supported these findings by suggesting a negative impact of AR positivity on tumor recurrence [<xref ref-type="bibr" rid="CR30">30</xref>]. Various clinical trials have evaluated the role of anti-androgens for the treatment of liver cancer with controversial outcome. In a systematic review, <italic>Di Maio</italic> et al. concluded that hormonal treatment should not be a part of the current management of HCC patients [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p>
        <p>There are different therapeutic strategies for HCC without metastasis. First of all local ablative therapies like percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and radiation therapy (RT) but effectiveness depends on the number and size of the tumors. Due to the tumor burden of our patient local ablative therapies such as RFA or surgery were not possible. TACE for bridging was recommended by the tumorboard, although a clear differentiation between HCA and carcinoma was not given. This minimally- invasive method can treat multiple tumors, can be easily repeated and is well established in the treatment algorithm for patients with advanced HCC [<xref ref-type="bibr" rid="CR33">33</xref>]. Embolization of HCA has been rarely reported, but appears to be a feasible therapeutic option [<xref ref-type="bibr" rid="CR34">34</xref>]. Our patient refused to take this option.</p>
        <p>In general liver transplantation is the therapy of choice for selected patients with HCC without the possibility of resection and extrahepatic metastasis [<xref ref-type="bibr" rid="CR35">35</xref>]. It is known, that patients exceeding Milan criteria for liver transplantation had a higher recurrence rate and lower survival rate than complying them. But also beyond the Milan criteria but within extended University of California, San Francisco (UCSF) criteria (single tumor &lt;6.5&#xA0;cm, maximum of three total tumors with none &gt;4.5&#xA0;cm, and cumulative tumor size &lt;8&#xA0;cm) a prolonged survival can be achieved. Survival rates beyond UCSF criteria were less than 50&#xA0;% at 5&#xA0;years [<xref ref-type="bibr" rid="CR36">36</xref>]. Following liver transplantation, our patient is still without any signs of tumor recurrence or metastasis.</p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="conclusion">
      <title>Conclusion</title>
      <p>In this case, 6&#xA0;years of chronic anabolic androgenic steroid abuse lead to HCA and HCC development with almost no normal liver tissue left. Not only bodybuilders but also trainers and physicians should be aware of the HCC risk when using or prescribing AAS.</p>
      <sec id="Sec10">
        <title>Consent</title>
        <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>AAS</term>
          <def>
            <p>Anabolic androgenic steroids</p>
          </def>
        </def-item>
        <def-item>
          <term>ALT</term>
          <def>
            <p>Alanine transaminase</p>
          </def>
        </def-item>
        <def-item>
          <term>AR</term>
          <def>
            <p>Androgen receptor</p>
          </def>
        </def-item>
        <def-item>
          <term>AST</term>
          <def>
            <p>Aspartate transaminase</p>
          </def>
        </def-item>
        <def-item>
          <term>AFP</term>
          <def>
            <p>Alfa-fetoprotein</p>
          </def>
        </def-item>
        <def-item>
          <term>CEUS</term>
          <def>
            <p>Contrast-enhanced ultrasonography</p>
          </def>
        </def-item>
        <def-item>
          <term>CHE</term>
          <def>
            <p>Cholinesterase</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p>C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>Computer tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>FNA</term>
          <def>
            <p>Fine needle aspiration</p>
          </def>
        </def-item>
        <def-item>
          <term>FSH</term>
          <def>
            <p>Follicle stimulating hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>GGT</term>
          <def>
            <p>Gamma-glutamyl transferase</p>
          </def>
        </def-item>
        <def-item>
          <term>HCA</term>
          <def>
            <p>Hepatocellular adenoma</p>
          </def>
        </def-item>
        <def-item>
          <term>HCC</term>
          <def>
            <p>Hepatocellular carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>INR</term>
          <def>
            <p>International normalized ratio</p>
          </def>
        </def-item>
        <def-item>
          <term>IVC</term>
          <def>
            <p>Inferior vena cava</p>
          </def>
        </def-item>
        <def-item>
          <term>LDH</term>
          <def>
            <p>Lactate dehydrogenase</p>
          </def>
        </def-item>
        <def-item>
          <term>LH</term>
          <def>
            <p>Luteinising hormone</p>
          </def>
        </def-item>
        <def-item>
          <term>MDRD</term>
          <def>
            <p>Modification of diet in renal disease</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>Magnet resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>PCT</term>
          <def>
            <p>Procalcitonin</p>
          </def>
        </def-item>
        <def-item>
          <term>PEI</term>
          <def>
            <p>Percutaneous ethanol injection</p>
          </def>
        </def-item>
        <def-item>
          <term>RFA</term>
          <def>
            <p>Radiofrequency ablation</p>
          </def>
        </def-item>
        <def-item>
          <term>RT</term>
          <def>
            <p>Radiation therapy</p>
          </def>
        </def-item>
        <def-item>
          <term>TACE</term>
          <def>
            <p>Transarterial chemoembolization</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>All authors listed have contributed sufficiently to the project to be included as authors, and all those who are qualified to be authors are listed in the author byline. To the best of our knowledge, no conflict of interest, financial or other, exists.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>PS carried out the concept and design of the case report, responsible for the acquisition, analysis and interpretation of data and drafted the manuscript. AP was responsible for the acquisition, sonography and for the revision of the manuscript for content. HJR was responsible for the acquisition, computed tomography and for the revision of the manuscript for content. BS was responsible for the acquisition, analysis and interpretation of data, technical support and for the revision of the manuscript for content. UL was responsible for the gene mutation analysis of &#xDF;-catenin and for the revision of the manuscript for content. AS was responsible for the acquisition, technical support and for the revision of the manuscript for content. MG was responsible for the acquisition, analysis and interpretation of data, sonography and for the revision of the manuscript for content. MM was responsible for the acquisition, analysis and interpretation of data, technical support and for the revision of the manuscript for content and study supervision. AV carried out the concept and design of the case report and was responsible for the acquisition, analysis and interpretation of data, technical support and for the final revision of the manuscript for content. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rooks</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Ory</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Ishak</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Strauss</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Greenspan</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>AP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidemiology of hepatocellular adenoma. The role of oral contraceptive use</article-title>
          <source>JAMA</source>
          <year>1979</year>
          <volume>242</volume>
          <issue>7</issue>
          <fpage>644</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.1979.03300070040020</pub-id>
          <pub-id pub-id-type="pmid">221698</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagasue</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yukaya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Androgen receptors in hepatocellular carcinoma and surrounding parenchyma</article-title>
          <source>Gastroenterology</source>
          <year>1985</year>
          <volume>89</volume>
          <issue>3</issue>
          <fpage>643</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1016/0016-5085(85)90463-9</pub-id>
          <pub-id pub-id-type="pmid">2991072</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farges</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dokmak</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Belghiti</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bedossa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Paradis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Changing trends in malignant transformation of hepatocellular adenoma</article-title>
          <source>Gut</source>
          <year>2011</year>
          <volume>60</volume>
          <issue>1</issue>
          <fpage>85</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1136/gut.2010.222109</pub-id>
          <pub-id pub-id-type="pmid">21148580</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Lerner</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Siegel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Feagler</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Majerus</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma</article-title>
          <source>Lancet</source>
          <year>1972</year>
          <volume>2</volume>
          <issue>7790</issue>
          <fpage>1273</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(72)92649-9</pub-id>
          <pub-id pub-id-type="pmid">4117807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Labrune</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Trioche</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Duvaltier</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Chevalier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Odievre</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature</article-title>
          <source>J Pediatr Gastroenterol Nutr</source>
          <year>1997</year>
          <volume>24</volume>
          <issue>3</issue>
          <fpage>276</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1097/00005176-199703000-00008</pub-id>
          <pub-id pub-id-type="pmid">9138172</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Velazquez</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Alter</surname>
              <given-names>BP</given-names>
            </name>
          </person-group>
          <article-title>Androgens and liver tumors: Fanconi&#x2019;s anemia and non-Fanconi&#x2019;s conditions</article-title>
          <source>Am J Hematol</source>
          <year>2004</year>
          <volume>77</volume>
          <issue>3</issue>
          <fpage>257</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.20183</pub-id>
          <pub-id pub-id-type="pmid">15495253</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gorayski</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Subhash</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular carcinoma associated with recreational anabolic steroid use</article-title>
          <source>Br J Sports Med</source>
          <year>2008</year>
          <volume>42</volume>
          <issue>1</issue>
          <fpage>74</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1136/bjsm.2007.03932</pub-id>
          <pub-id pub-id-type="pmid">18178686</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hernandez-Nieto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bruguera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bombi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rozman</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone)</article-title>
          <source>Cancer</source>
          <year>1977</year>
          <volume>40</volume>
          <issue>4</issue>
          <fpage>1761</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(197710)40:4&lt;1761::AID-CNCR2820400454&gt;3.0.CO;2-C</pub-id>
          <pub-id pub-id-type="pmid">198105</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Socas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zumbado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Perez-Luzardo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hernandez</surname>
              <given-names>JR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature</article-title>
          <source>Br J Sports Med</source>
          <year>2005</year>
          <volume>39</volume>
          <issue>5</issue>
          <fpage>e27</fpage>
          <pub-id pub-id-type="doi">10.1136/bjsm.2004.013599</pub-id>
          <pub-id pub-id-type="pmid">15849280</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hardt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stippel</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Odenthal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Holscher</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Dienes</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Drebber</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Development of hepatocellular carcinoma associated with anabolic androgenic steroid abuse in a young bodybuilder: a case report</article-title>
          <source>Case Reports Pathol</source>
          <year>2012</year>
          <volume>2012</volume>
          <fpage>195607</fpage>
          <pub-id pub-id-type="doi">10.1155/2012/195607</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huss</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nehles</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Binot</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wardelmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mittler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kleine</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>beta-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis</article-title>
          <source>Histopathology</source>
          <year>2013</year>
          <volume>62</volume>
          <issue>2</issue>
          <fpage>294</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2559.2012.04355.x</pub-id>
          <pub-id pub-id-type="pmid">23020601</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzaferro</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Regalia</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Doci</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Andreola</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pulvirenti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bozzetti</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis</article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>334</volume>
          <issue>11</issue>
          <fpage>693</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199603143341104</pub-id>
          <pub-id pub-id-type="pmid">8594428</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dombrowski</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Flaschka</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Klotz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>von Netzer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lehnert</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatocellular neoplasms after intrahepatic transplantation of ovarian fragments into ovariectomized rats</article-title>
          <source>Hepatology</source>
          <year>2006</year>
          <volume>43</volume>
          <issue>4</issue>
          <fpage>857</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.21124</pub-id>
          <pub-id pub-id-type="pmid">16557532</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Fischer SE. Hepatocellular carcinoma arising in hepatic adenoma: diagnostic and management implications. Diagn Histopathology. 2014;20(6):257&#x2013;61.</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SU</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male</article-title>
          <source>Korean J Intern Med</source>
          <year>2009</year>
          <volume>24</volume>
          <issue>2</issue>
          <fpage>147</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.3904/kjim.2009.24.2.147</pub-id>
          <pub-id pub-id-type="pmid">19543495</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ronald</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Woodfield</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McCall</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koea</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Hepatic adenomas in male patients</article-title>
          <source>HPB (Oxford)</source>
          <year>2004</year>
          <volume>6</volume>
          <issue>1</issue>
          <fpage>25</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1080/13651820310020846</pub-id>
          <pub-id pub-id-type="pmid">18333041</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stoot</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Coelen</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>De Jong</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Dejong</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases</article-title>
          <source>HPB (Oxford)</source>
          <year>2010</year>
          <volume>12</volume>
          <issue>8</issue>
          <fpage>509</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1477-2574.2010.00222.x</pub-id>
          <pub-id pub-id-type="pmid">20887318</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pilati</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Letouze</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nault</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Imbeaud</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Boulai</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Calderaro</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation</article-title>
          <source>Cancer Cell</source>
          <year>2014</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>428</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2014.03.005</pub-id>
          <pub-id pub-id-type="pmid">24735922</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rebouissou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Blanc</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Saric</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sa Cunha</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry</article-title>
          <source>Hepatology</source>
          <year>2007</year>
          <volume>46</volume>
          <issue>3</issue>
          <fpage>740</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.21743</pub-id>
          <pub-id pub-id-type="pmid">17663417</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zucman-Rossi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jeannot</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nhieu</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Scoazec</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Guettier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rebouissou</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC</article-title>
          <source>Hepatology</source>
          <year>2006</year>
          <volume>43</volume>
          <issue>3</issue>
          <fpage>515</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.21068</pub-id>
          <pub-id pub-id-type="pmid">16496320</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arrive</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Flejou</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Vilgrain</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Belghiti</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Najmark</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zins</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hepatic adenoma: MR findings in 51 pathologically proved lesions</article-title>
          <source>Radiology</source>
          <year>1994</year>
          <volume>193</volume>
          <issue>2</issue>
          <fpage>507</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1148/radiology.193.2.7972769</pub-id>
          <pub-id pub-id-type="pmid">7972769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grazioli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Federle</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Ichikawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Balzano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nalesnik</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Madariaga</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients</article-title>
          <source>Radiology</source>
          <year>2000</year>
          <volume>216</volume>
          <issue>2</issue>
          <fpage>395</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="doi">10.1148/radiology.216.2.r00jl38395</pub-id>
          <pub-id pub-id-type="pmid">10924560</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hussain</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>van den Bos</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Dwarkasing</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Kuiper</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>den Hollander</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular adenoma: findings at state-of-the-art magnetic resonance imaging, ultrasound, computed tomography and pathologic analysis</article-title>
          <source>Eur Radiol</source>
          <year>2006</year>
          <volume>16</volume>
          <issue>9</issue>
          <fpage>1873</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1007/s00330-006-0292-4</pub-id>
          <pub-id pub-id-type="pmid">16708218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Murphy-Lavallee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Focal nodular hyperplasia and hepatic adenoma: differentiation with low-mechanical-index contrast-enhanced sonography</article-title>
          <source>AJR Am J Roentgenol</source>
          <year>2008</year>
          <volume>190</volume>
          <issue>1</issue>
          <fpage>58</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="doi">10.2214/AJR.07.2493</pub-id>
          <pub-id pub-id-type="pmid">18094294</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Psatha</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Semelka</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Armao</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Woosley</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Firat</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular adenomas in men: MRI findings in four patients</article-title>
          <source>J Magn Reson Imaging</source>
          <year>2005</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>258</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1002/jmri.20375</pub-id>
          <pub-id pub-id-type="pmid">16028257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Claudon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dietrich</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Cosgrove</surname>
              <given-names>DO</given-names>
            </name>
            <name>
              <surname>Kudo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nolsoe</surname>
              <given-names>CP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS</article-title>
          <source>Ultrasound Med Biol</source>
          <year>2013</year>
          <volume>39</volume>
          <issue>2</issue>
          <fpage>187</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ultrasmedbio.2012.09.002</pub-id>
          <pub-id pub-id-type="pmid">23137926</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laumonier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bioulac-Sage</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zucman-Rossi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Balabaud</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Trillaud</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification</article-title>
          <source>Hepatology</source>
          <year>2008</year>
          <volume>48</volume>
          <issue>3</issue>
          <fpage>808</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.22417</pub-id>
          <pub-id pub-id-type="pmid">18688875</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalili</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Haider</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Guindi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Optimization of imaging diagnosis of 1&#x2013;2&#xA0;cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization</article-title>
          <source>J Hepatol</source>
          <year>2011</year>
          <volume>54</volume>
          <issue>4</issue>
          <fpage>723</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2010.07.025</pub-id>
          <pub-id pub-id-type="pmid">21156219</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagasue</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Galizia</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kohno</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection</article-title>
          <source>Ann Surg</source>
          <year>1989</year>
          <volume>209</volume>
          <issue>4</issue>
          <fpage>424</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1097/00000658-198904000-00006</pub-id>
          <pub-id pub-id-type="pmid">2539062</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boix</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Castells</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bruix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sole</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bru</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection</article-title>
          <source>J Hepatol</source>
          <year>1995</year>
          <volume>22</volume>
          <issue>6</issue>
          <fpage>616</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/0168-8278(95)80217-7</pub-id>
          <pub-id pub-id-type="pmid">7560855</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Maio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Daniele</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pignata</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>De Maio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Morabito</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is human hepatocellular carcinoma a hormone-responsive tumor?</article-title>
          <source>World J Gastroenterol</source>
          <year>2008</year>
          <volume>14</volume>
          <issue>11</issue>
          <fpage>1682</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.14.1682</pub-id>
          <pub-id pub-id-type="pmid">18350599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Di Maio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>De Maio</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Morabito</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#x2019;Aniello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>De Feo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hormonal treatment of human hepatocellular carcinoma</article-title>
          <source>Ann N Y Acad Sci</source>
          <year>2006</year>
          <volume>1089</volume>
          <fpage>252</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="doi">10.1196/annals.1386.007</pub-id>
          <pub-id pub-id-type="pmid">17261772</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Llovet</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Real</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Montana</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Planas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Coll</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aponte</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>359</volume>
          <issue>9319</issue>
          <fpage>1734</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(02)08649-X</pub-id>
          <pub-id pub-id-type="pmid">12049862</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>YI</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Feasibility of transcatheter arterial chemoembolization for hepatic adenoma</article-title>
          <source>J Vasc Interv Radiol</source>
          <year>2007</year>
          <volume>18</volume>
          <issue>7</issue>
          <fpage>862</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jvir.2007.04.014</pub-id>
          <pub-id pub-id-type="pmid">17609445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Carithers</surname>
              <given-names>RL</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Aasld: AASLD practice guidelines: evaluation of the patient for liver transplantation</article-title>
          <source>Hepatology</source>
          <year>2005</year>
          <volume>41</volume>
          <issue>6</issue>
          <fpage>1407</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.20704</pub-id>
          <pub-id pub-id-type="pmid">15880505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duffy</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Vardanian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farmer</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Ghobrial</surname>
              <given-names>RM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA</article-title>
          <source>Ann Surg</source>
          <year>2007</year>
          <volume>246</volume>
          <issue>3</issue>
          <fpage>502</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1097/SLA.0b013e318148c704</pub-id>
          <pub-id pub-id-type="pmid">17717454</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
